Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)

Journal of Chemotherapy

Volumn 25, Issue 4, 2013, Pages 239-246

  Ades, Felipe ^a   de Azambuja, Evandro ^a   Daugaard, Gedske ^b   Ameye, Lieveke ^a   Moulin, Camilo ^c   Paesmans, Marianne ^a   De Jong, Daphne ^d   Decoster, Lore ^e   De Greve, Jacques ^e   Ismael, Gustavo ^f   Møller, Anne Kirstine ^b   Piccart, Martine ^a   Awada, Ahmad ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Rigshospitalet   (Denmark)

^c EORTC DATA CENTER   (Belgium)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^f Hospital Amaral Carvalho   (Brazil)

Author keywords

Cancer of unknown primary; CUP; CupPrint ; Gene expression profiling; Metastatic tumour

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; BIOPSY; CANCER OF UNKNOWN PRIMARY SITE; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; RNA EXTRACTION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84880962780     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000085     Document Type: Article

References (32)

1. Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22Suppl 6:vi64-68.
2. Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol. 2009;69(3):271-8.
3. Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. ASCO [Internet]. [cited 2011 Oct 19]. Available from: http://www.asco.org/ascov2/ Meetings/Abstracts?&vmview5abst_detail_view&confID565& abstractID534102
4. occult.pdf [Internet]. [cited 2011 Oct 25]. Available from:http://www.nccn.org/professionals/physician_gls/PDF/occult.pdf
5. Schapira DV, Jarrett AR. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med. 1995;155(19):2050-4.
6. Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielmann M, et al. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med. 1988;148(9):2035-9.
7. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995;13(8):2094-103.
8. Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009;19(3):731-44.
9. Dumur CI, Lyons-Weiler M, Sciulli C, Garrett CT, Schrijver I, Holley TK, et al. Interlaboratory performance of a microarraybased gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn. 2008;10(1):67-77.
10. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11(10):3766-72.
11. Tothill RW, Kowalczyk A, Rischin D, Bousioutas A, Haviv I, Van Laar RK, et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res. 2005;65(10):4031-40.
12. Van Laar RK, Ma X-J, De Jong D, Wehkamp D, Floore AN, Warmoes MO, et al. Implementation of a novel microarraybased diagnostic test for cancer of unknown primary. Int J Cancer. 2009;125(6):1390-7.
13. Bridgewater J, Van Laar R, Floore A, Van'T Veer L. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer. 2008;98(8):1425- 30.
14. Horlings HM, Van Laar RK, Kerst J-M, Helgason HH, Wesseling J, Van der Hoeven JJM, et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol. 2008;26(27):4435-41.
15. Morawietz L, Floore A, Stork-Sloots L, Folprecht G, Buettner R, Rieger A, et al. Comparison of histopathological and gene expression-based typing of cancer of unknown primary. Virchows Arch. 2010;456(1):23-9.
16. Ma X-J, Patel R, Wang X, Salunga R, Murage J, Desai R, et al. Molecular classification of human cancers using a 92-gene realtime quantitative polymerase chain reaction assay. Arch Pathol Lab Med. 2006;130(4):465-73.
17. Centeno BA, Bloom G, Chen D-T, Chen Z, Gruidl M, Nasir A, et al. Hybrid model integrating immunohistochemistry and expression profiling for the classification of carcinomas of unknown primary site. J Mol Diagn. 2010;12(4):476-86.
18. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11(10):3766-72.
19. Talantov D, Baden J, Jatkoe T, Hahn K, Yu J, Rajpurohit Y, et al. A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn. 2006;8(3):320-9.
20. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 2001;61(20):7388-93.
21. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008;26(27):4442-8.
22. Monzon FA, Medeiros F, Lyons-Weiler M, Henner WD. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test. Diagn Pathol. 2010;5:3.
23. Greco FA, Rodriguez GI, Shaffer DW, Hermann R, Litchy S, Yardley DA, et al. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist. 2004;9(6):644-52.
24. Erlander MG, Ma X-J, Kesty NC, Bao L, Salunga R, Schnabel CA. Performance and clinical evaluation of the 92-gene realtime PCR assay for tumor classification. J Mol Diagn. 2011;13(5):493-503.
25. Kerr SE, Schnabel CA, Sullivan PS, Zhang Y, Singh V, Carey B, et al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res. 2012;18(14):3952-60.
26. Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma X-J, Hainsworth JD. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist. 2010;15(5):500-6.
27. Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute. JCO. 2013;31(2):217-23.
28. Michiels S, Kramar A, Koscielny S. Multidimensionality of microarrays: statistical challenges and (im)possible solutions. Mol Oncol. 2011;5(2):190-6.
29. Genetic testing or clinical assessment in determining the need for chemotherapy in women with breast cancer that involves no more than 3 lymph nodes. Full Text View. ClinicalTrials.gov [Internet]. [cited 2011 Nov 29]. Available from: http://clinical trials.gov/ct2/show/NCT00433589?term5mindact&rank51
30. Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for nodenegative breast cancer (The TAILORx Trial). Full Text View. ClinicalTrials.gov [Internet]. [cited 2011 Nov 29]. Available from: http://clinicaltrials.gov/ct2/show/NCT00310180?term5tailorX&rank51
31. Haas I, Hoffmann TK, Engers R, Ganzer U. Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). Eur Arch Otorhinolaryngol. 2002;259(6):325-33.
32. Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28(33):4877-83.